Nicola Steele

2.5k total citations
41 papers, 1.4k citations indexed

About

Nicola Steele is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nicola Steele has authored 41 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Nicola Steele's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (9 papers) and Occupational and environmental lung diseases (8 papers). Nicola Steele is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (9 papers) and Occupational and environmental lung diseases (8 papers). Nicola Steele collaborates with scholars based in United Kingdom, Italy and United States. Nicola Steele's co-authors include Robert Brown, Jane A. Plumb, Paul W. Finn, Johann S. de Bono, Laura Vidal, P. Buhl-Jensen, Jette Tjørnelund, Poul Knoblauch, C Zeller and Charlotte S. Wilhelm-Benartzi and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Bone and Joint Surgery and Oncogene.

In The Last Decade

Nicola Steele

37 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicola Steele United Kingdom	18	722	677	344	218	156	41	1.4k
Allyson J. Ocean United States	18	477 0.7×	1.1k 1.7×	496 1.4×	214 1.0×	205 1.3×	81	1.9k
Dousheng Bai China	22	531 0.7×	329 0.5×	237 0.7×	251 1.2×	317 2.0×	91	1.3k
Claudia Sandomenico Italy	18	404 0.6×	562 0.8×	366 1.1×	132 0.6×	124 0.8×	52	987
Ehsan Malek United States	15	744 1.0×	538 0.8×	95 0.3×	126 0.6×	261 1.7×	113	1.3k
Claudio Cerchione Italy	20	574 0.8×	585 0.9×	129 0.4×	54 0.2×	121 0.8×	123	1.3k
Kei Kunimasa Japan	19	352 0.5×	786 1.2×	860 2.5×	99 0.5×	251 1.6×	98	1.4k
Thomas J. Semrad United States	15	257 0.4×	395 0.6×	237 0.7×	117 0.5×	162 1.0×	51	890
Xiuyi Zhi China	17	355 0.5×	327 0.5×	355 1.0×	66 0.3×	164 1.1×	66	874
Erwan Pencreach France	17	323 0.4×	350 0.5×	200 0.6×	54 0.2×	248 1.6×	35	797
Hazem El‐Osta United States	16	262 0.4×	434 0.6×	234 0.7×	77 0.4×	109 0.7×	35	893

Countries citing papers authored by Nicola Steele

Since Specialization

Citations

This map shows the geographic impact of Nicola Steele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Steele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Steele more than expected).

Fields of papers citing papers by Nicola Steele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Steele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Steele. The network helps show where Nicola Steele may publish in the future.

Co-authorship network of co-authors of Nicola Steele

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Steele. A scholar is included among the top collaborators of Nicola Steele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Steele. Nicola Steele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Datta, Indrani, Alokkumar Jha, Arushi Arora, et al.. (2024). 1215P United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer. Annals of Oncology. 35. S782–S783. 1 indexed citations

Blackhall, Fiona, Adel Samson, K. Franks, et al.. (2023). 1502TiP A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1. Annals of Oncology. 34. S846–S846. 3 indexed citations

Hiley, Crispin T., T. Ahmad, Matthew Krebs, et al.. (2023). LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC. Annals of Oncology. 34. S1314–S1314.

Lindsay, Colin R., M. Button, Nicola Steele, et al.. (2022). 1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review. Annals of Oncology. 33. S1061–S1062. 2 indexed citations

Woll, Penella J., Piers Gaunt, Sarah Danson, et al.. (2022). Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 171. 26–33. 30 indexed citations

Grosso, Federica, Nicola Steele, Anna K. Nowak, et al.. (2018). 213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. Journal of Thoracic Oncology. 13(4). S128–S128. 1 indexed citations

Barlési, Fabrice, Makoto Nishio, Manuel Cobo, et al.. (2018). IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii743–viii744. 44 indexed citations

Ready, Neal, Anna F. Farago, Filippo de Braud, et al.. (2018). Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. Journal of Thoracic Oncology. 14(2). 237–244. 233 indexed citations

Fennell, Dean A., Emma Kirkpatrick, Kelly Cozens, et al.. (2018). CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 19(1). 233–233. 30 indexed citations

10.

Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations

11.

Woll, Penella J., Piers Gaunt, Nicola Steele, et al.. (2017). P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC. Journal of Thoracic Oncology. 12(1). S704–S705. 17 indexed citations

12.

Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. Annals of Oncology. 28. ix74–ix74. 5 indexed citations

13.

Krebs, Matthew, James Spicer, Nicola Steele, et al.. (2017). P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. Journal of Thoracic Oncology. 12(1). S1272–S1273. 3 indexed citations

14.

Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations

15.

Zeller, C, Wei Dai, Nicola Steele, et al.. (2012). Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 31(42). 4567–4576. 226 indexed citations

16.

Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2010). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology. 67(6). 1273–1279. 45 indexed citations

17.

Fraser, Judith, et al.. (2010). Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. European Journal of Cancer. 47(2). 215–220. 22 indexed citations

18.

Steele, Nicola, Paul W. Finn, Robert Brown, & Jane A. Plumb. (2009). Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. British Journal of Cancer. 100(5). 758–763. 118 indexed citations

19.

Steele, Nicola, Jane A. Plumb, Laura Vidal, et al.. (2008). A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(3). 804–810. 211 indexed citations

20.

Steele, Nicola, et al.. (2005). Thromboprophylaxis in pelvic and acetabular trauma surgery - The role of early treatment with low-molecularweight heparin. Journal of Bone and Joint Surgery. 209–212. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact